Metsera’s Long-Acting GLP-1 Drug Shows Promising 7.5% Weight Loss in 36 Days, Paving Way for Monthly Dosing

Clinical Trial Results:
Metsera's Phase 1 trial of MET-097, a long-acting GLP-1 receptor agonist, demonstrated a 7.5% reduction in body weight from baseline at day 36.

Dosing Potential:
The drug's 380-hour half-life suggests the possibility for once-monthly dosing without titration, offering a more convenient and scalable treatment option.

Safety Profile:
The trial showed a favorable safety profile with mostly mild and transient gastrointestinal adverse events, consistent with marketed and clinical-stage GLP-1 compounds.

Future Plans:
Metsera plans to launch Phase 2b trials in Q4 2024, with data anticipated in the first half of 2025.

Competitive Edge:
The results position MET-097 as a potentially ultra-long acting, potent, and well-tolerated GLP-1 drug candidate, matching or exceeding currently available and investigational GLP-1 and GLP-1 combination drugs.